https://enzodesignbuild.com
The drug is administered through subcutaneous injections and was first permitted by the FDA in 2002. The apparent offender for Humira’s fall from grace is growing biosimilar competitors. Since the drug misplaced key patent protections in 2023, a number of copycats have hit the market, including Amgen’s Amjevita, Celltrion’s Yuflyma, Cordavis and Sandoz’s Hyrimoz and Boehringer Ingelheim’s Cyltezo. Another main driver of Humira’s market erosion is CVS Caremark’s transfer in April 2024 to take away the branded drug from its main national formularies in favor o
Like
Comment
Share
